AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
09 Noviembre 2023 - 8:00AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a
regenerative medicine company leading the development and
commercialization of first-in-class devices and autologous cellular
therapies for skin restoration, today announced it has entered into
a distribution agreement with PolyMedics Innovations GmbH, to
strategically expand its global presence to Europe.
Under the terms of the agreement, PolyMedics
Innovations will serve as the Company’s exclusive distributor of
RECELL® in Germany, Austria, and Switzerland, with an option to
expand to additional European markets in the future.
PolyMedics Innovations, a privately-owned company
specializing in the commercialization of innovative biomaterials
and systems for the treatment of wounds, operates a robust
distribution network of over 40 global markets. AVITA Medical will
leverage their deep expertise, well-established infrastructure, and
extensive knowledge of these markets to effectively expand its
reach.
“Our partnership with PolyMedics Innovations
represents the first step of our strategic global expansion,” said
Jim Corbett, Chief Executive Officer of AVITA Medical. “Their
proven track record and expertise in the global distribution of
innovative wound treatments make them an ideal partner. We look
forward to a successful collaboration that will enable us to reach
more patients worldwide.”
Christian Planck, Chief Executive Officer of
PolyMedics Innovations added, “we are excited to partner with AVITA
Medical. Our specialized sales team's deep focus on burns and
trauma seamlessly aligns with the targeted procedures for RECELL,
and we expect to deliver strong results while elevating the
standard of care for patients in Germany, Austria, and
Switzerland.”
About AVITA Medical, Inc.AVITA
Medical® is a regenerative medicine company leading the development
and commercialization of devices and autologous cellular therapies
for skin restoration. The RECELL® System technology platform,
approved by the Food and Drug Administration for the treatment of
thermal burn wounds and full-thickness skin defects and for
repigmentation of stable depigmented vitiligo lesions, harnesses
the regenerative properties of a patient’s own skin to create
Spray-On Skin™ cells. Delivered at the point-of-care, RECELL
enables improved clinical outcomes. RECELL is the catalyst of a new
treatment paradigm and AVITA Medical is leveraging its proven and
differentiated capabilities to develop first-in-class cellular
therapies for multiple indications.
In international markets, our products are approved
under the RECELL System brand to promote skin healing in a wide
range of applications including burns, full-thickness skin defects,
and vitiligo. The RECELL System is TGA-registered in Australia,
received CE-mark approval in Europe and has PMDA approval in
Japan.
To learn more, visit www.avitamedical.com.
About PolyMedics Innovations
GmbHPolyMedics Innovations (PMI) is a R&D-driven
specialist in innovative biomaterials for the effective treatment
of wounds. PMI is an owner-managed German Mittelstand Company
headquartered in Denkendorf, Germany with a subsidiary in Atlanta,
USA. Distribution covers over 40 markets globally. PMI’s
state-of-the-art manufacturing plant is located in Germany. PMI is
a market leader in burn care in the DACH countries (Germany,
Austria, and Switzerland) with a strong presence in the US, LATAM
and Asia. The company is renowned for its commitment to delivering
innovative medical solutions and services, catering to the diverse
needs of healthcare providers and patients. PMI's portfolio offered
to its customers in the DACH region encompasses a range of
cutting-edge products, including SUPRATHEL®, NovoSorb® BTM, SUPRA
SDRM® and Nexobrid®. With a strong focus on customer access, sales,
marketing, and a dedicated medical team, PMI is poised to
facilitate rapid and professional expansion in the medical
industry.
Forward-Looking Statements This
press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this press release include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational, and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward-looking statement contained in
this press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. Applicable risks and uncertainties
include, among others, the timing and realization of regulatory
approvals of our products; physician acceptance, endorsement, and
use of our products; failure to achieve the anticipated benefits
from approval of our products; the effect of regulatory actions;
product liability claims; risks associated with international
operations and expansion; and other business effects, including the
effects of industry, economic or political conditions outside of
the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this press
release. Investors are encouraged to read our publicly available
filings for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and we undertake no
obligation to update or revise any of these statements.
Authorized for release by the Chief Financial
Officer of AVITA Medical, Inc.
Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
Avita Medical (NASDAQ:RCEL)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Avita Medical (NASDAQ:RCEL)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024